Vivani Medical, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 24, 2025. The filing covers corporate governance matters including the election of directors, ratification of the independent auditor, and advisory approval of executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on stockholder voting outcomes.
Material Changes and Voting Results
A quorum was established with 37,097,099 of 59,243,903 shares represented. The following proposals were submitted and approved:
- Proposal 1 (Election of Directors): All six nominees were elected to the Board of Directors. Votes ranged from approximately 24.76 million to 24.95 million "For" votes per director.
- Proposal 2 (Ratification of Auditor): Stockholders ratified the appointment of BPM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 36,538,077 "For" versus 98,316 "Against".
- Proposal 3 (Executive Compensation): Stockholders approved the compensation of named executive officers on a non-binding advisory basis. The vote was 23,052,944 "For" versus 594,065 "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (59,243,903) and the percentage of shares represented at the meeting (approximately 62.6%).
- Confirm the tenure of the newly elected directors, which extends until the 2026 Annual Meeting.
- Note the significant number of broker non-votes (11,776,254) on the director election and executive compensation proposals.
- Review the full proxy statement for details on the specific compensation packages approved under Proposal 3.